Fig C. Kaplan–Meier survival estimates for the lag between trial completion and publication according to registration timing. Kaplan-Meier survival estimates
Fig D. Kaplan–Meier survival estimates for the lag between trial completion and publication according to trial affiliation. Kaplan-Meier survival estimates
0
1
2
3
4
5
6 7 8 9 10 11 12 13 14 analysis time (years)
Number at risk University 63 47 32 24 19 16 12 10 Practice 1 0 0 0 0 0 0 0 Hospital 16 15 13 10 9 9 7 7 University Hospital
9 0 6
8 0 5
5 0 4
3 0 3
Practice
2 0 2
1 0 2
0 0 0
Fig E. Kaplan–Meier survival estimates for the lag between trial completion and publication according to geographic origin.
0.00 0.25 0.50 0.75 1.00
Kaplan-Meier survival estimates
0
1
2
3
4
5 6 7 8 9 10 11 12 13 14 analysis time (years)
Number at risk Europe 47 Asia 11 N. America 14 S. America/ Africa 8
40 5 10 7
34 1 6 4
27 1 3 3
22 1 2 3
21 0 2 2
17 0 1 1
15 0 1 1
Europe N. America
14 0 1 0
12 0 1 0
9 0 0 0
6 0 0 0
4 0 0 0
3 0 0 0
0 0 0 0
Asia S. America/Africa
0.00 0.25 0.50 0.75 1.00
Fig F. Kaplan–Meier survival estimates for the lag between trial completion and publication according to sponsor. Kaplan-Meier survival estimates
0
Number at risk Internal Government Commercial Other
Fig G. Kaplan–Meier survival estimates for the lag between trial completion and publication according to number of trial centers. Kaplan-Meier survival estimates
Fig H. Kaplan–Meier survival estimates for the lag between trial completion and publication according to trial size.
0.00
0.25
0.50
0.75
1.00
Kaplan-Meier survival estimates
0
1
2
3
4
5 6 7 8 9 10 11 12 13 14 analysis time (years)
Number at risk 66 48 32 23 17 14 10 9 Not large 5 5 4 3 3 3 1 0 Large Not large
8 0
6 0
3 0
3 0
Large
2 0
2 0
0 0
0.00 0.25 0.50 0.75 1.00
Fig I. Kaplan–Meier survival estimates for the lag between trial completion and publication according to eligible patients’ age. Kaplan-Meier survival estimates
Fig K. Kaplan–Meier survival estimates for the lag between trial completion and publication according to journal type. Kaplan-Meier survival estimates
0
1
2
3
4
5 6 7 8 9 10 11 12 13 14 analysis time (years)
Number at risk Non-specialty 12 6 2 Specialty 21 18 13
0 7
0 4
0 3
0 0
0 0
Non-specialty
0 0
0 0
0 0
0 0
0 0
Specialty
0 0
0 0
0.00
0.25
0.50
0.75
1.00
Fig L. Kaplan–Meier survival estimates for the lag between trial completion and publication according to journal type (electronic publishing). Kaplan-Meier survival estimates
0
1
2
3
4
5
Number at risk No epub 15 12 Epub 18 12
7 8
3 4
2 2
2 1
6 7 8 9 10 11 42 13 14 analysis time (years) 0 0
No epub
0 0
0 0
0 0
0 0 Epub
0 0
0 0
0 0
0 0
0.00
0.25
0.50
0.75
1.00
Fig M. Kaplan–Meier survival estimates for the lag between trial completion and publication according to their findings. Kaplan-Meier survival estimates
0
1
2
3
4
5 6 7 8 9 10 11 12 13 14 analysis time (years)
Number at risk Non-positive results 14 10 Positive results 15 10
8 4
4 1
2 1
1 1
0 0
0 0
Not positive
0 0
0 0
0 0
0 0
Positive
0 0
0 0
0 0
Fig N. Geographic content of the two assessed trial registries.
ISRCTN
ClinicalTrials. gov
19
1
1
2
2
3
4
18
5 6 7 8 9
17 10 16 3 1 3
Germany UK
2
Italy
1 3 5 7 9 11 13 15 17 19
11 15 14 13 12
Austria Brazil China Egypt Germany India Italy Sweden UK notgiven
2 4 6 8 10 12 14 16 18
Belgium Canada Colombia France Hong Kong Iran Kuwait Syria USA